Regeneron Pharmaceuticals (REGN) said late Thursday its initial phase 1b trials data of linvoseltamab in combination with carfilzomib or bortezomib to treat refractory multiple myeloma showed a 90% objective response rate after a 15-month follow-up.
Almost 76% of patients achieved a complete response, the company said.
Adverse events were recorded in over 50% of the patients, while grade 3 adverse events included neutropenia, cytokine release syndrome, diarrhea, and thrombocytopenia. Infections developed in 91% of patients, and serious adverse events occurred in 83%.
The company will present trial data at the American Society of Clinical Oncology 2025 Annual Meeting on June 2.
Shares were down 2% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。